Blueprint Medicines Corp Stock Price, News & Analysis

Blueprint Medicines (BPMC) announced key updates during its Investor Day on November 1, 2022, reiterating total revenue guidance of $180-$200 million for 2022. The company plans to submit a supplemental New Drug Application for AYVAKIT® for non-advanced systemic mastocytosis and aims for a U.S. launch in mid-2023. The recent SYMPHONY trial data supports the clinical activity of BLU-945 in EGFR-mutant lung cancer. Blueprint's five-year strategy aims for four or more marketed products by 2027, enhancing its commercial footprint.

Blueprint Medicines Corporation (Nasdaq: BPMC) will host an Investor Day on November 1, 2022, at 8:30 a.m. ET in New York City. The event aims to showcase the company's plans for enhancing precision medicine accessibility, featuring presentations from management and a panel discussion with experts in mastocytosis and immunology. Additionally, Blueprint Medicines will report its third quarter 2022 financial results on the same day, with a live webcast available on their website.

Blueprint Medicines Corporation (Nasdaq: BPMC) announced on October 6, 2022, that its Compensation Committee granted non-qualified stock options for 11,381 shares and 5,688 restricted stock units (RSUs) to eight new employees, effective October 1, 2022. This is part of the 2020 Inducement Plan, aimed at attracting new talent. The options have an exercise price of $65.89 per share, equal to the closing price on September 30, 2022, and will vest over a four-year period. The RSUs will also vest over four years, contingent on continued employment.

Blueprint Medicines Corporation (Nasdaq: BPMC) announced on September 6, 2022, that its Compensation Committee granted stock options for 18,170 shares and 9,083 restricted stock units (RSUs) to thirteen new employees as part of the 2020 Inducement Plan. The options have an exercise price of $73.83 per share, equal to the closing price on the grant date of September 1, 2022. Vesting for options occurs over four years, while RSUs vest 25% annually, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the publication of research indicating significant symptom burden in systemic mastocytosis (SM) patients. Published in the journal CANCER, the study highlights severe symptoms including pain, frequent emergency visits, and a substantial impact on quality of life. Results showed that 66% of patients faced work interference due to symptoms, with over 50% requiring multiple medications. The research emphasizes the urgent need for improved therapies to enhance the quality of life for those affected by SM.

Blueprint Medicines Corporation (NASDAQ: BPMC) reported positive results from the registrational Part 2 of the PIONEER clinical trial for AYVAKIT (avapritinib), showing significant improvements in patients with non-advanced systemic mastocytosis. Highlighted metrics include a mean change in total symptom score reduction of 15.6 points at 24 weeks (p=0.003) and over 50% of patients achieving a reduction in serum tryptase. The company plans to file a supplemental new drug application with the FDA in Q4 2022, potentially paving the way for AYVAKIT to be a groundbreaking treatment for this condition.

Guardant Health and Blueprint Medicines presented new data at the IASLC 2022 World Conference on Lung Cancer, revealing that the EGFR C797X mutation is a prevalent resistance mechanism to osimertinib for advanced non-small cell lung cancer (NSCLC) patients. The cumulative incidence of this mutation was found to be 12.5% after first-line treatment. The collaboration utilized the GuardantINFORM platform to analyze data from over 2,000 patients, emphasizing the need for next-generation EGFR inhibitors to combat C797X-driven resistance in NSCLC.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of stock options and restricted stock units (RSUs) to 14 new employees, effective August 1, 2022. The 29,359 stock options have an exercise price of $50.60, matching the closing price on the grant date. Each option will vest 25% after one year, with further monthly vesting. The 14,675 RSUs will also vest 25% annually after the first year. This move aligns with the company's 2020 Inducement Plan aimed at attracting new talent as per NASDAQ Listing Rules.

Blueprint Medicines Corporation (NASDAQ: BPMC) reported Q2 2022 revenues of $36.5 million, up from $27.3 million a year ago. AYVAKIT revenues reached $28.5 million, marking a 20% increase. The company plans to share topline data from the PIONEER trial for AYVAKIT in non-advanced systemic mastocytosis (SM) in August 2022. A strategic license for a KIT exon 13 inhibitor was granted to IDRx, potentially yielding $217.5 million in future milestones. The cash position stood at $947.2 million, down from $1.034 billion in December 2021.